TAG and the LAT CAB celebrate the Indian Patent Office’s decision to NOT grant a patent on the HCV combination treatment glecaprevir/pibrentasvir, aka Mavyret® or Maviret® manufactured by AbbVie. More
WHO warns current rates of progress are insufficient to meet all 2030 viral hepatitis elimination targets, underscoring the urgent need to accelerate prevention, testing, and treatment efforts worldwide. More
As the United Nations embarks on far-reaching institutional reform, a major new report from the International Drug Policy Consortium delivers a stark warning: global drug control is failing. More
WHO launches first-ever implementation handbook to accelerate country action on hepatitis elimination. More
In a commentary, published in The Lancet Gastroenterology & Hepatology, frontline voices reveal how recent global health funding cuts are already disrupting hepatitis B and C services worldwide. More
